Format

Send to

Choose Destination
Hum Vaccin Immunother. 2019 Oct 21. doi: 10.1080/21645515.2019.1677437. [Epub ahead of print]

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.

Author information

1
Sanofi Pasteur , Taguig , Philippines.
2
Medical Corporation Heishinkai ToCROM Clinic , Tokyo , Japan.
3
Medical Corporation Heishinkai OCROM Clinic , Osaka , Japan.
4
Sanofi K.K , Tokyo , Japan.
5
Sanofi Pasteur , Swiftwater , PA , USA.

Abstract

A trivalent high-dose inactivated influenza vaccine has been licensed in healthy adults ≥65 years of age and provides better protection against influenza infection and related complications than trivalent standard-dose vaccine. This phase I/II clinical trial (NCT03233217), conducted at two sites in Japan, examined the safety and immunogenicity of a quadrivalent formulation of the high-dose inactivated influenza vaccine (IIV4-HD). Healthy adults ≥65 years of age were randomized to receive IIV4-HD by intramuscular injection (n=60), IIV4-HD by subcutaneous injection (n=60), or a quadrivalent standard-dose inactivated influenza vaccine (IIV4-SD) by subcutaneous injection (n=55). Irrespective of administration route, post-vaccination (day 28-35) hemagglutination inhibition geometric mean titers and seroconversion rates were higher for IIV4-HD than for IIV4-SD. Hemagglutination inhibition geometric mean titers and seroconversion rates were also higher for intramuscular than subcutaneous administration of IIV4-HD. Solicited reactions were more common in participants who received IIV4-HD administered subcutaneously than in those who received IIV4-HD administered intramuscularly or IIV4-SD administered subcutaneously. Unsolicited adverse events were similar between the vaccine groups, and no safety signals were detected. This study showed that IIV4-HD administered by either intramuscular or subcutaneous injection was well tolerated and highly immunogenic in healthy Japanese adults ≥65 years of age. Although this study was descriptive, the results add to the evidence that high-dose inactivated influenza vaccines are more immunogenic than standard-dose vaccines in this age group and that intramuscular administration provides greater immunogenicity and lower reactogenicity than subcutaneous administration.

KEYWORDS:

Japan; Quadrivalent influenza vaccine; elderly adults; high-dose influenza vaccine; immunogenicity; intramuscular; safety; subcutaneous

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center